Group 1 - The core point of the article is that Glenmark Pharmaceuticals' stock surged by 10% following the announcement of a $700 million agreement for a blood cancer drug [1] Group 2 - The agreement is significant for Glenmark, indicating strong market interest and potential revenue growth in the oncology sector [1] - The rise in stock price reflects investor confidence in the company's strategic direction and product pipeline [1]